Surgical treatment of non-functioning pancreatic neuroendocrine tumours based on three clinical scenarios
- PMID: 27863693
- DOI: 10.1016/j.ciresp.2016.07.008
Surgical treatment of non-functioning pancreatic neuroendocrine tumours based on three clinical scenarios
Abstract
Introduction: The treatment of patients with non-functioning pancreatic neuroendocrine tumours (NFPNET) is resection in locally pancreatic disease, or with resectable liver metastases. There is controversy about unresectable liver disease.
Methods: We analysed the perioperative data and survival outcome of 63 patients who underwent resection of NFPNET between 1993 and 2012. They were divided into 3 scenarios: A, pancreatic resection (44patients); B, pancreatic and liver resection in synchronous resectable liver metastases (12patients); and C, pancreatic resection in synchronous unresectable liver metastases (6patients). The prognostic factors for survival and recurrence were studied.
Results: Distal pancreatectomy (51%) and pancreaticoduodenectomy (38%) were more frequently performed. Associated surgery was required in 44% of patients, including synchronous liver resections in 9patients. Two patients received a liver transplant during follow-up. According to the WHO classification they were distributed into G1: 10 (16%), G2: 45 (71%), and G3: 8 (13%). The median hospital stay was 11days. Postoperative morbidity and mortality were 49% and 1.6%, respectively. At the closure of the study, 43 (68%) patients were still alive, with a mean actuarial survival of 9.6years. The WHO classification and tumour recurrence were risk factors of mortality in the multivariate analysis. The median actuarial survival by scenarios was 131months (A), 102months (B), and 75months (C) without statistically significant differences.
Conclusions: Surgical resection is the treatment for NFPNET without distant disease. Resectable liver metastases in well-differentiated tumours must be resected. The resection of the pancreatic tumour with unresectable synchronous liver metastasis must be considered in well-differentiated NFPNET. The WHO classification grade and recurrence are risk factors of long-term mortality.
Keywords: Duodenopancreatectomía cefálica; Liver metastases; Liver resection; Metástasis hepáticas; Non-functioning pancreatic neuroendocrine tumour; Pancreatic resection; Pancreaticoduodenectomy; Resección hepática; Resección pancreática; Tumor neuroendocrino pancreático no funcionante.
Copyright © 2016 AEC. Publicado por Elsevier España, S.L.U. All rights reserved.
Similar articles
-
Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.Eur J Surg Oncol. 2017 Feb;43(2):372-379. doi: 10.1016/j.ejso.2016.09.011. Epub 2016 Sep 30. Eur J Surg Oncol. 2017. PMID: 27742480
-
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.Arch Surg. 2003 Aug;138(8):859-66. doi: 10.1001/archsurg.138.8.859. Arch Surg. 2003. PMID: 12912744
-
Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.Eur J Surg Oncol. 2014 Nov;40(11):1564-71. doi: 10.1016/j.ejso.2014.06.004. Epub 2014 Jun 30. Eur J Surg Oncol. 2014. PMID: 25086992
-
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy.Updates Surg. 2020 Mar;72(1):39-45. doi: 10.1007/s13304-020-00710-z. Epub 2020 Jan 29. Updates Surg. 2020. PMID: 31997233
-
Pancreatic cancer and liver metastases: state of the art.Updates Surg. 2016 Sep;68(3):247-251. doi: 10.1007/s13304-016-0407-7. Epub 2016 Nov 10. Updates Surg. 2016. PMID: 27832445 Review.
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical